Features of α-HBDH in COVID-19 patients with different ages,outcomes and clinical types: a cohort study

  1. Haoming Zhu
  2. Gaojing Qu
  3. Hui Yu
  4. Guoxin Huang
  5. Lei Chen
  6. Meiling Zhang
  7. Shanshan Wan
  8. Bin Pei

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

Background

Coronavirus disease-2019 (COVID-19) has spread all over the world and brought extremely huge losses. At present, there is no study to systematically analyse the features of hydroxybutyrate dehydrogenase (α-HBDH) in COVID-19 patients with different ages, clinical types and outcomes.

Methods

Electronic medical records including demographics, clinical manifestation, α-HBDH test results and outcomes of 131 hospitalized COVID-19 patients, with confirmed result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection, were extracted and analyzed.

Results

The α-HBDH value in ≥61 years old group, severe group and critical group, death group all increased at first and then decreased, while no obvious changes were observed in other groups. And there were significant differences of the α-HBDH value among different age groups (P<0.001), clinical type groups (P<0.001) and outcome groups (P<0.001). The optimal scale regression model showed that α-HBDH value (P<0.001) and age (P<0.001) were related to clinical type.

Conclusions

α-HBDH value increases in some COVID-19 patients, obviously in ≥61 years old, death and critical group, indicating that patients in these three groups suffer from more serious tissues and organs damage, higher α -HBDH value and risk of death. The obvious difference between death and survival group in early stage may provide a approach to judge the prognosis. The accuracy of the model to distinguish severe/critical type and other types is 85.84%, suggesting that α-HBDH could judge the clinical type of COVID-19 patients accurately. In brief, α-HBDH is an important indicator to judge the severity and prognosis of COVID-19.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.10.29.20222612: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study was approved by the ethics review board of Xiangyang No.1 People’s Hospital (No.2020GCP012) and registered at the Chinese Clinical Trial Registry as ChiCTR2000031088.
    Consent: Informed consent from patients has been exempted since this study is an observational cohort study that does not involve patients’ personal privacy.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The data were traced back to 23 January and followed up to 28 March, 2020. 2.4 Statistical Analysis: All statistical analyses were performed by SPSS 20.0.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    However, this study has several limitations. All the patients in the study come from the single hospital, and the sample size is small. This study is a retrospective cohort study, which fails to detect and analyze the daily α-HBDH in patients and may lose some information.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2020.10.29.20222612v1 on medRxiv